Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics


Alpine Immune Sciences, Inc. (ALPN)

Today's Latest Price: $3.51 USD

0.10 (2.93%)

Updated May 27 3:16pm

Add ALPN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ALPN Stock Summary

  • With a price/sales ratio of 22.39, Alpine Immune Sciences Inc has a higher such ratio than 93.94% of stocks in our set.
  • With a year-over-year growth in debt of 390.63%, Alpine Immune Sciences Inc's debt growth rate surpasses 95.45% of about US stocks.
  • Revenue growth over the past 12 months for Alpine Immune Sciences Inc comes in at 625.9%, a number that bests 98.87% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alpine Immune Sciences Inc are WVE, MGEN, VYGR, MCRB, and KALV.
  • Visit ALPN's SEC page to see the company's official filings. To visit the company's web site, go to www.alpineimmunesciences.com.
ALPN Daily Price Range
ALPN 52-Week Price Range

ALPN Stock Price Chart More Charts


ALPN Price/Volume Stats

Current price $3.51 52-week high $5.35
Prev. close $3.41 52-week low $2.05
Day low $3.45 Volume 11,700
Day high $3.55 Avg. volume 17,676
50-day MA $2.93 Dividend yield N/A
200-day MA $3.33 Market Cap 65.24M

Alpine Immune Sciences, Inc. (ALPN) Company Bio


Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.


ALPN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ALPN Latest Social Stream


Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about Alpine Immune Sciences Inc that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I

Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I

Yahoo | April 20, 2020

What You Must Know About Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Beta Value

Anyone researching Alpine Immune Sciences, Inc. (NASDAQ:ALPN) might want to consider the historical volatility of the...

Yahoo | April 13, 2020

Alpine Immune Sciences Sees Hammer Chart Pattern: Time to Buy?

Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

Yahoo | April 7, 2020

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.

Yahoo | March 30, 2020

Alpine Immune Sciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...

Yahoo | March 30, 2020

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo 18.38%
3-mo 12.50%
6-mo 15.84%
1-year -28.95%
3-year -62.34%
5-year N/A
YTD -8.59%
2019 4.35%
2018 -67.14%
2017 25.00%
2016 -71.06%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8807 seconds.